Literature DB >> 27095424

Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes.

Emily R Pfeiffer1, Raquel Vega2, Patrick M McDonough2, Jeffrey H Price2, Ross Whittaker2.   

Abstract

INTRODUCTION: A priority in the development and approval of new drugs is assessment of cardiovascular risk. Current methodologies for screening compounds (e.g. HERG testing) for proarrhythmic risk lead to many false positive and false negative results, resulting in the attrition of potentially therapeutic compounds in early development, and the advancement of other candidates that cause adverse effects. With improvements in the technologies of high content imaging and human stem cell differentiation, it is now possible to directly screen compounds for arrhythmogenic tendencies in human stem cell derived cardiomyocytes (hSC-CMs).
METHODS: A training panel of 90 compounds consisting of roughly equal numbers of QT-prolonging and negative control (non-QT-prolonging) compounds, and a follow-up blinded study of 35 compounds including 16 from the 90 compound panel and 2 duplicates, were evaluated for prolongation of the calcium transient in hSC-CMs using kinetic image cytometry (KIC), a specialized form of high content analysis.
RESULTS: The KIC-hSC-CM assay identified training compounds that prolong the calcium transient with 98% specificity, 97% precision, 80% sensitivity, and 89% accuracy in predicting clinical QT prolongation by these compounds. The follow-up study of 35 blinded compounds confirmed the reproducibility and strong diagnostic accuracy of the assay. DISCUSSION: The correlation of the KIC-hSC-CM results to clinical observations met or surpassed traditional preclinical assessment of cardiac risk utilizing animal models. Thus, the KIC-hSC-CM assay, which can be accomplished in high throughput and at relatively low cost, is an effective new model system for testing chemicals for cardiovascular risk.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3Rs; Action potential; Calcium transient; Cardiac safety pharmacology; Cisapride (PubChem CID: 2769); Comprehensive in vitro Proarrhythmia Assay (CiPA); Dofetilide (PubChem CID: 71329); Droperidol (PubChem CID: 3168); Fluo 4AM (PubChem CID: 4060965); Haloperidol (PubChem CID: 3559); High-throughput; Human stem cell derived cardiomyocytes; Kinetic image cytometry; Methods; Pimozide (PubChem CID: 16362); QT; Quinidine (PubChem CID: 441074); Sematilide (PubChem CID: 58505); Sotalol (PubChem CID: 66245); Thioridazine (PubChem CID: 5452)

Mesh:

Year:  2016        PMID: 27095424     DOI: 10.1016/j.vascn.2016.04.007

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  13 in total

1.  Assessing Drug-Induced Long QT and Proarrhythmic Risk Using Human Stem-Cell-Derived Cardiomyocytes in a Ca2+ Imaging Assay: Evaluation of 28 CiPA Compounds at Three Test Sites.

Authors:  Hua Rong Lu; Haoyu Zeng; Ralf Kettenhofen; Liang Guo; Ivan Kopljar; Karel van Ammel; Fetene Tekle; Ard Teisman; Jin Zhai; Holly Clouse; Jennifer Pierson; Michael Furniss; Armando Lagrutta; Frederick Sannajust; David J Gallacher
Journal:  Toxicol Sci       Date:  2019-08-01       Impact factor: 4.849

Review 2.  Bringing new dimensions to drug discovery screening: impact of cellular stimulation technologies.

Authors:  Elena Molokanova; Mark Mercola; Alex Savchenko
Journal:  Drug Discov Today       Date:  2017-02-04       Impact factor: 7.851

3.  High-content analysis and Kinetic Image Cytometry identify toxicity and epigenetic effects of HIV antiretrovirals on human iPSC-neurons and primary neural precursor cells.

Authors:  Alyson S Smith; Soneela Ankam; Chen Farhy; Lorenzo Fiengo; Ranor C B Basa; Kara L Gordon; Charles T Martin; Alexey V Terskikh; Kelly L Jordan-Sciutto; Jeffrey H Price; Patrick M McDonough
Journal:  J Pharmacol Toxicol Methods       Date:  2022-02-08       Impact factor: 2.285

4.  Assay of Calcium Transients and Synapses in Rat Hippocampal Neurons by Kinetic Image Cytometry and High-Content Analysis: An In Vitro Model System for Postchemotherapy Cognitive Impairment.

Authors:  Patrick M McDonough; Natalie L Prigozhina; Ranor C B Basa; Jeffrey H Price
Journal:  Assay Drug Dev Technol       Date:  2017-07       Impact factor: 1.738

5.  Thorough QT/QTc in a Dish: An In Vitro Human Model That Accurately Predicts Clinical Concentration-QTc Relationships.

Authors:  Alexander D Blanchette; Fabian A Grimm; Chimeddulam Dalaijamts; Nan-Hung Hsieh; Kyle Ferguson; Yu-Syuan Luo; Ivan Rusyn; Weihsueh A Chiu
Journal:  Clin Pharmacol Ther       Date:  2018-12-02       Impact factor: 6.875

Review 6.  Human iPSC modeling of heart disease for drug development.

Authors:  Anna P Hnatiuk; Francesca Briganti; David W Staudt; Mark Mercola
Journal:  Cell Chem Biol       Date:  2021-03-18       Impact factor: 8.116

7.  CIRM tools and technologies: Breaking bottlenecks to the development of stem cell therapies.

Authors:  Lila R Collins; Kelly A Shepard
Journal:  Stem Cells Transl Med       Date:  2020-07-03       Impact factor: 6.940

8.  An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes.

Authors:  Wesley L McKeithan; Alex Savchenko; Michael S Yu; Fabio Cerignoli; Arne A N Bruyneel; Jeffery H Price; Alexandre R Colas; Evan W Miller; John R Cashman; Mark Mercola
Journal:  Front Physiol       Date:  2017-10-11       Impact factor: 4.566

9.  A human population-based organotypic in vitro model for cardiotoxicity screening.

Authors:  Fabian A Grimm; Alexander Blanchette; John S House; Kyle Ferguson; Nan-Hung Hsieh; Chimeddulam Dalaijamts; Alec A Wright; Blake Anson; Fred A Wright; Weihsueh A Chiu; Ivan Rusyn
Journal:  ALTEX       Date:  2018-07-08       Impact factor: 6.043

10.  All-Optical Electrophysiology Refines Populations of In Silico Human iPSC-CMs for Drug Evaluation.

Authors:  Michelangelo Paci; Elisa Passini; Aleksandra Klimas; Stefano Severi; Jari Hyttinen; Blanca Rodriguez; Emilia Entcheva
Journal:  Biophys J       Date:  2020-04-04       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.